News Focus
News Focus
icon url

geocappy1

09/01/18 10:58 AM

#328364 RE: EndoTarget #328359

We won’t own it In two years
icon url

biopharm

09/01/18 11:03 AM

#328365 RE: EndoTarget #328359

ET, good post and all valid points for current condition but after all has happened in the past I don't trust much of anything of what may be in the works

Maybe all your points come true to the tune of $4 Billion cap which actually fits into my very recent thoughts of a $75 buyout

To make numbers easy 50M into 4B = $75 pps

Now maybe some long-term contracts are well placed and 4B market cap is undervalued and we don't have a set of puppet BODs that would jump at a $75 buyout when we hit $50 pps so the premium is justified and they cover all bases

Also maybe....maybe much of my past speculation was correct and the IP assets were always astronomical as Steve King stated publically and publically stated "dozens of collaborations" ...etc etc

The question will ALWAYS remain in any natural longtime long shareholder and realizing the value ...in why Stafford undermined / down plays the IP which coincides with current BODs failures to set up an open market competitive bidding for all to bid and the still very much under the radar talks or dare mentioning of the words PS Targeting by current BODs

Cost of Dart Neuroscience must be too much ...

Cost to keep Dart Executions website up must be too much

John Springs Stafford III and Ronin Hedge Group friends ...wonder if they talked with Carlyle Group friends latley about PS Targeting IP and Biomarkers

I guess there is a piece of the pie for everyone ....except landscapers : )





icon url

The Other Guy

09/01/18 7:34 PM

#328376 RE: EndoTarget #328359

Astronomical was King’s lie to keep interest in the IP of Peregrine. He was untruthful many times (where is that partnership we were promised?).